SHELTON, Conn., June 7, 2016 /PRNewswire/ -- NanoViricides,
Inc. (NYSE MKT: NNVC) (the "Company"), a pioneer in developing
nanomedicines that directly attack viruses using biomimicry,
announced today that it will present at the BIO2016
International Convention on Wednesday June
8, 2016, in San Francisco,
California.
The presentation by the Company's CEO, Eugene Seymour, MD, MPH, is scheduled to begin
at 11am and will report recent
progress as well as explain the nature of the NanoViricides
technology.
NanoViricides is actively developing topical antivirals against
several different herpesvirus indications, namely, cold sores
caused by HSV-1, genital ulcers caused by HSV-2, shingles caused by
VZV (the chickenpox virus), and ocular herpes keratitis. The total
market size for these indications is estimated to be several
billions of dollars. The Company has previously shown complete
survival in lethally infected animals with HSV-1 H129 strain
infection. The H129 strain is derived from a clinical strain and is
a highly infectious, neurotropic virus that causes very high
morbidity. Since then the Company has been engaged in further drug
optimization and process engineering developments necessary for
performing manufacture under current Good Manufacturing Practices
(cGMP). A cGMP product is needed for human clinical trials in the
USA.
NanoViricides is one of very few small bio-pharma companies that
possess their own pilot scale cGMP manufacturing facilities.
NanoViricides believes this internal manufacturing capability helps
in rapid progress to clinical trials for all of our novel,
industry-leading nanomedicine drug candidates. Internal
manufacturing also maximally protects our intellectual property. In
addition, our multi-kilogram batch production capacity may allow
market entry as a stand-alone pharmaceutical company while enabling
early revenues, once a product is licensed.
NanoViricides is also working on developing a broad-spectrum
nanoviricide to treat diseases caused by several flaviviruses.
These flaviviruses include all four subtypes of dengue viruses, as
well as the recent epidemic Zika virus, among others. There are no
assurances that this work will lead to an effective drug in a rapid
timeframe.
NanoViricides is also developing two broad-spectrum drugs to
treat influenza virus infections, namely, Injectable FluCide™ for
the treatment of severely ill, hospitalized patients, and Oral
FluCide™ for the treatment of our-patients.
The presentation will be available on the Company website at
http://www.nanoviricides.com/investorinfo.html.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Shingles,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo -
http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-to-present-at-the-bio2016-international-convention---on-june-8-2016-at-11am-pacific-time-300280674.html
SOURCE NanoViricides, Inc.